Follow-The-Filings

Security

ABUS

Arbutus Biopharma Corp. · COM

Equity holders as of 2026 Q1 (each manager’s latest book)

7 owners 2 new max 0.0% (Vanguard Group Inc.)

grid → activity →
owners 7
max % 0.0%
tracked value $52M
qoq N 2 A 3 R 2

holders

sorted by % of portfolio · long equity only

manager % port activity shares value history
Vanguard Group Inc. 2025 Q4 stale 0.0% Add 0.00 pp 9,242,437 $44M hist
Ken Griffin - Citadel Advisors LLC 2026 Q1 0.0% Add 0.00 pp 677,138 $3M hist
Israel Englander - Millennium Management LLC 2026 Q1 0.0% New 0.0% 642,448 $3M hist
D. E. Shaw & Co., Inc. 2026 Q1 0.0% Reduce 0.00 pp 143,201 $644 hist
Dmitry Balyasny - Balyasny Asset Management L.P. 2026 Q1 0.0% Reduce 0.00 pp 125,521 $565 hist
Cliff Asness - Aqr Capital Management LLC 2026 Q1 0.0% Add 0.00 pp 23,819 $107 hist
Joel Greenblatt - Gotham Asset Management, LLC 2026 Q1 0.0% New 0.0% 17,321 $78 hist

7 current · options excluded

financials

US-GAAP annual · as tagged in Form 10-K · fiscal years · values link to the SEC filing

Income statement

Metric FY2023 FY2024 FY2025
Revenue $18.14M $6.17M $14.08M
Gross profit — — —
Gross margin — — —
Net income -$72.85M -$69.92M -$33.5M
Net margin * -401.6% -1133.0% -237.9%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $132.03M $127.32M $94.46M
Total non-current assets * $12.37M $4.39M $162,000
Total assets $144.4M $131.71M $94.62M
Total current liabilities $22.49M $15.62M $6.01M
Total non-current liabilities * $15.9M $18.72M $12.04M
Total equity $106.02M $97.37M $76.58M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$85.94M -$64.85M -$39.64M
Cash from investing $50.77M $22.95M $15.58M
Cash from financing $30.65M $52M $5.72M
Net change in cash -$4.49M $10.04M -$18.32M

Source: SEC companyfacts (US-GAAP 10-K) · * = computed (not a single XBRL tag) · fiscal year as labeled by the issuer · not adjusted or audited by Follow-The-Filings

ownership over time

filing count by report period · click a bar for that quarter’s holders